teachey-davidPrinciple Investigator: Dr. David Teachey

Disease: Autoimmune Lymphoproliferative Syndrome

Research Description: Autoimmune Lymphoproliferative Syndrome (ALPS) is a rare childhood autoimmune disease. Patients suffer from enlarged lymph nodes and spleen, increased infections and anemia. ALPS patients may spend as many as 5-10 days in the hospital each month and may not survive beyond their teens. Dr. Teachey tested the repurposed generic drug sirolimus, a drug used to prevent rejection in organ transplants, in mice. Using the results of this CWR-funded mouse study, he then conducted a pilot clinical study among six patients at the Children’s Hospital of Philadelphia, in which five of the six patients were in complete remission in 90 days. Patient hospitalizations declined, and patients have continued to survive and thrive on sirolimus. The cost to treat these patients has also significantly decreased, resulting in lower medical bills.

CWR funding role: Primary funder

Publication:  British Journal of Haematology; Blood

Since publication:

→ Data are supporting off-label clinical use

→ Findings from project led to additional applications of repurposed treatment in other pediatric autoimmune diseases.

Sign up for our eNewsletter today!


First Name

Cures Within Reach


All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes.  CWR is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Monday the 25th. Copyright 2018 Cures Within Reach.